# DESCRIPTION

## BACKGROUND OF THE INVENTION

- introduce fracture healing problem
- discuss role of mesenchymal stem/progenitor cells
- motivate need for new therapeutic approaches

## BRIEF SUMMARY OF THE INVENTION

- introduce compound of formula (I)
- describe compound of formula (II)
- describe compound of formula (III)
- introduce composition for controlled local delivery
- outline methods of promoting bone formation and treating diseases

## DETAILED DESCRIPTION OF THE INVENTION

- introduce Bortezomib conjugates for bone formation
- describe applications and methods for bone disorders

### Definitions

- define technical and scientific terms
- introduce articles "a" and "an"
- define "about" in measurable values
- define "abnormal" in organisms and cells
- define "disease" and "disorder"
- define "alleviated" in disease or disorder
- define "patient", "subject", and "individual"
- define "pharmaceutical composition"
- define "therapeutic" and "treatment"
- define "effective amount" and "pharmaceutically acceptable"

### DESCRIPTION

- introduce carbamate linkers
- describe therapeutic agent conjugation
- discuss linker properties
- detail cleavable bond options
- explain linker stability influence
- describe aromatic ring substituents
- introduce dye conjugation
- outline synthesis techniques
- define compound formulas
- describe Notch inhibitor conjugation

### Preparation of the Compounds of the Invention

- describe general synthetic schemes
- illustrate non-limiting embodiments of synthesis
- discuss stereoisomers and optically active forms
- outline methods for preparing prodrugs and isotopically-labeled compounds

### Therapeutic Methods

- describe method for promoting bone formation
- outline methods for treating diseases and disorders
- discuss pharmaceutical compositions and administration

### Pharmaceutical Compositions and Administration

- define pharmaceutical compositions
- describe administration routes
- detail unit dose and bulk preparations
- list additional ingredients
- describe oral formulations
- detail tablet preparation methods
- describe parenteral formulations
- describe pulmonary formulations
- discuss additional formulation options

### Controlled Release Formulations and Drug Delivery Systems

- describe controlled release formulations

## EXAMPLES

- describe synthesis and study of BP-Btz1

### Example 1: Synthesis of BP-Btz1

- synthesize urethane diol 2 and BP-Btz1

### Example 2: Study of Osteoblast Regulation in TNF-Mediated Bone Loss

- motivate UPS-mediated protein modification in bone repair
- study bone-targeted conjugate compound BP-Btz1

### Example 3: Study of Osteoblast Regulation in TNF-Mediated Bone Loss

- investigate role of E3 ligase in bone using knockout mice
- design and synthesize bone-targeted Bortezomib conjugates
- test bone-targeted Bortezomib in regulating osteoblasts and osteoclasts vitro
- determine effect of BT-Btz conjugates on OB differentiation and protein degradation in vitro
- examine effect of BT-Btz conjugates on OC formation and bone resorption in vitro
- outline statistical plan and data analysis

### Example 4: Protein Modification in Bone Cell Regulation

- hypothesize UPS inhibition promotes fracture healing
- observe ubiquitinated proteins in fracture calluses
- design, synthesize, and test bone-targeted Bortezomib conjugates in vitro
- design and synthesize new bone-targeted Bortezomib conjugates
- examine bioactivity of BP-Btz conjugates on OB differentiation and OC formation in vitro
- examine bone-targeted Bortezomib conjugates on bone volume and regeneration in vivo
- examine efficacy of BP-Btz for prevention of OVX-induced bone loss
- examine efficacy of BP-Btz conjugates on bone fracture repair in aged mice
- statistical plan and data analysis

### Example 5: Bone-Targeted Bortezomib Prevents OVX- and Myeloma-Induced Bone Loss with Less Systemic Adverse Effects More Effectively than Bortezomib

- demonstrate BP-Btz1 prevents OVX- and MM-induced bone loss with fewer systemic adverse effects than Btz

### Example 6: Synthetic Examples

- synthesize ((((2-(2-((R)-3-methyl-1-((S)-3-phenyl-2-(pyrazine-
- synthesize ((2-(2-((R)-3-methyl-1-((S)-3-phenyl-2-(pyrazine-
- synthesize tetraethyl (5-(2-((tert-butyldimethylsilyl)oxy)ethyl)-9,9,
- synthesize tetraethyl ((2-(bis(2-hydroxyethyl)amino)acetamido)methylene)
- synthesize ((4-(2-((R)-3-methyl-1-((S)-3-phenyl-2-(pyrazine-

